Skip to content

Katherine Stueland, Chief Executive Officer at GeneDx, sold WGS on Sep 16, 2026

Data as of Oct 16

▼ SELL$155K1,648 shares at $94.26Katherine Stueland Chief Executive OfficerWGS GeneDx Holdings Corp.
Watch WGS
Traded
Sep 16, 2026
Disclosed
Sep 18, 2026
Filed
2 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Katherine Stueland, Chief Executive Officer at GeneDx, sold WGS on Sep 16, 2026TRADEDDISCLOSED
WGSSimilar stocks (XLV — its sector index fund), rebased to WGS's price on the disclosure day
WGS since disclosure
−37.1%
after the sale
Similar stocks (XLV) since disclosure
+4.9%
XLV — its sector index fund

Change in closing price from Sep 18, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLKatherine Stueland Chief Executive OfficerWGS GeneDx Holdings Corp.$407Kdisclosed Sep 18 · filed 2 days after the trade
  2. ▼ SELLKatherine Stueland Chief Executive OfficerWGS GeneDx Holdings Corp.$148Kdisclosed Sep 18 · filed 2 days after the trade
  3. ▼ SELLKatherine Stueland Chief Executive OfficerWGS GeneDx Holdings Corp.$301Kdisclosed Sep 18 · filed 2 days after the trade
  4. ▼ SELLKatherine Stueland Chief Executive OfficerWGS GeneDx Holdings Corp.$14.1Kdisclosed Sep 18 · filed 2 days after the trade

See every trade on WGS →